Immunic (NASDAQ:IMUX) Given “Outperform” Rating at Wedbush

Immunic (NASDAQ:IMUX)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued on Thursday, Benzinga reports. They presently have a $45.00 price target on the stock. Wedbush’s price objective suggests a potential upside of 269.16% from the company’s previous close.

Several other equities research analysts have also commented on IMUX. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Immunic in a research report on Thursday. Roth Capital reissued a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. Wolfe Research began coverage on shares of Immunic in a research report on Friday, May 22nd. They set an “outperform” rating for the company. B. Riley Financial reduced their target price on shares of Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Finally, LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Immunic presently has a consensus rating of “Buy” and a consensus target price of $47.25.

Immunic Stock Performance

Immunic stock opened at $12.19 on Thursday. The stock has a market cap of $166.27 million, a PE ratio of -2.78 and a beta of 1.41. Immunic has a one year low of $5.06 and a one year high of $17.43. The stock has a fifty day moving average of $14.81 and a 200 day moving average of $13.07.

Immunic (NASDAQ:IMUX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. As a group, sell-side analysts predict that Immunic will post -3.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp purchased a new stake in shares of Immunic in the first quarter worth $187,000. Braidwell LP bought a new stake in shares of Immunic during the 2nd quarter valued at $9,914,000. Avidity Partners Management LP lifted its stake in shares of Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after buying an additional 2,000,000 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Immunic during the 1st quarter valued at $1,020,000. Finally, Bank of America Corp DE boosted its holdings in Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after buying an additional 143,689 shares during the period. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.